These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17127957)

  • 21. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung cancer: looking ahead in 2004.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Barni S
    Anticancer Drugs; 2011 Nov; 22(10):1010-9. PubMed ID: 21970852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 27. The TAILOR study: to agree or to disagree?
    Moro-Sibilot D; Perol D; Chabaud S; Cadranel J; Audigier Valette C; Perol M
    Lung Cancer; 2014 Jun; 84(3):315-6. PubMed ID: 24751106
    [No Abstract]   [Full Text] [Related]  

  • 28. Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
    Ganti AK
    Cancer Invest; 2010 Jun; 28(5):515-25. PubMed ID: 20073576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
    Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
    Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
    Ku GY; Haaland BA; de Lima Lopes G
    Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
    Oh IJ; Ban HJ; Kim KS; Kim YC
    Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.
    Wang F; Wang LD; Li B; Sheng ZX
    Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):396-401. PubMed ID: 22019482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adjuvant or neoadjuvant chemotherapy in non-small cell bronchial cancers? Arguments in favor of choosing neoadjuvant chemotherapy].
    Depierre A
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S33-6. PubMed ID: 12538933
    [No Abstract]   [Full Text] [Related]  

  • 35. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 37. [Perspectives and future developments of epidermal growth factor receptors inhibitors].
    Soria JC
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S18-20. PubMed ID: 17242641
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting resistance in lung cancer.
    Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718
    [No Abstract]   [Full Text] [Related]  

  • 39. [Erlotinib in the treatment of NSCLC: current and novel prospects from the ASCO 2006].
    Longo F; Giovanni M
    Tumori; 2006; 92(5):suppl 13-22. PubMed ID: 17168450
    [No Abstract]   [Full Text] [Related]  

  • 40. Epidermal growth factor receptor mutations: a new insight.
    Belani CP
    Clin Lung Cancer; 2004 May; 5(6):328. PubMed ID: 15217529
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.